Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pelthos Therapeutics (PTHS) Other Operating Expenses (2024 - 2025)

Pelthos Therapeutics has reported Other Operating Expenses over the past 2 years, most recently at $26.7 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $26.7 million for Q4 2025, up 476.23% from a year ago — trailing twelve months through Dec 2025 was $11.9 million (up 180.59% YoY), and the annual figure for FY2025 was $5.5 million, changed.
  • Other Operating Expenses for Q4 2025 was $26.7 million at Pelthos Therapeutics, up from -$17.0 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for PTHS hit a ceiling of $26.7 million in Q4 2025 and a floor of -$17.0 million in Q3 2025.